


CLAIMS

1. A compound of general formula I:



wherein

R₁ are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl;

R₃ groups are each independently selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, nitro, azido, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group and substituted or unsubstituted acyl

R₄ groups are each independently selected from NR₂, O and S; and


R₂ groups are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or

unsubstituted aryl, substituted or unsubstituted alkoxy and substituted or unsubstituted acyl,

or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

2. The compound according to claim 1, having the following formula


II



wherein R₁, R₂, R₃ and R₄ are as defined in claim 1.


3. The compound according to claims 1 or 2, wherein R₁ are each independently selected from substituted or unsubstituted alkyl and substituted or unsubstituted alkylidene.

4. The compound according to any of claims 1 to 3, wherein R₂ are each independently selected from H and substituted or unsubstituted alkyl.
5. The compound according to any of the preceding claims, wherein R₃ are each independently selected from H and substituted or unsubstituted aryl.
6. The compound according to any of the preceding claims, wherein R₄ are each O.
7. The compound according to any of the preceding claims having the following formula




or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

8. The compound according to claim 7, having the following stereochemistry



9. A process for producing a compound as defined in claim 1 which comprises synthesising a oxazole/thiazole/imidazole fragment, and introducing an aminoacidic fragment.
10. A process for preparing a compound as defined in claim 1 which comprises cultivating a strain of a microorganism capable of producing it.
11. A process according to claim 10, wherein the compound prepared is IB-01211 of formula:

37



12. A process according to claims 10 or 11, wherein the microorganism is an actinomycete.

13. A process according to claim 12, wherein the microorganism is the substantially pure culture strain ES7-008, available under accession number CECT 3358, from the Colección Española de Cultivos Tipo at the University of Valencia, Spain.

14. A pharmaceutical composition comprising a compound as defined in any of claims 1 to 8, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof, and a pharmaceutically acceptable diluent or carrier.

15. Use of a compound as defined in any of claims 1 to 8, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof, in the preparation of a medicament.

16. The use according to claim 14, wherein the preparation of a medicament is for the treatment of cancer.

17. A method of treatment of cancer which comprises administering an effective amount of a comopund as defined in any of claims 1 to 8.